Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: eico20 who wrote (1580)	12/15/2015 12:50:13 AM
From: Mirror Image	of 2026

Eico - Honestly, I have not put too much effort in deciphering the clinical probabilities of Fismpemifene's success. Why? First of all. It's not my area of expertise. Secondly, I put in a ton of work ( in the past ) to decipher Vitaros' clinical probabilities and I happened to get it right. Do I feel rewarded? The short answer is NO! This is my view about Fispemifene's probabilities. The company needs financing. Everybody knows that. I have said in the past that I thought that the next Binary event ( share price wise ) was the results in on the Fispemifene studies. The Company is due with results from that study around the end of the 1Q 2016. I believe they are planning on Financing around that event. Whether it's before, during or right after that event - only they know. But it signals me that their bet is on a positive outcome. Or else the financing would have happened already. I think I will leave the experts opine in their areas of expertise. Just my thoughts.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next